Our clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus and myositis are now recruiting.

MusCAARTes™ Trial

Clinical trial for patients with muscle-specific tyrosine kinase myasthenia gravis

A Phase 1, Open-label, Safety and Dose-finding Study of Autologous Muscle-specific Tyrosine Kinase Chimeric Autoantibody Receptor T Cells (MuSK-CAART) in Subjects With Anti-MuSK-antibody-positive Myasthenia Gravis, Sponsored by Cabaletta Bio, Inc.

What is Myasthenia Gravis?

Muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG) is a rare but potentially severe disease, in which patients develop disease-causing autoantibodies that specifically target the MuSK protein in the neuromuscular junction.

Learn About Our Trial

What is a clinical trial?

A clinical research study is a medical study that helps to answer important questions about an investigational medication or product, such as:

  • How safe is it?
  • What is a safe amount, or dose?
  • Does it work?
  • What dose might work best?

All medications must be tested in clinical research studies before they can be approved to prescribe to patients. Without people taking part in these studies, we would have no new medications.

What is the MusCAARTes™ Phase 1 Trial?

This phase 1 study is being conducted to evaluate the safety of various dosing regimens of an investigational cell therapy, MuSK-CAART, that can be given to patients with anti-MuSK antibody positive Myasthenia Gravis (MuSK MG), who have active disease. It is sponsored by Cabaletta Bio, Inc. About 24 people with MuSK MG are expected to take part.

What is MuSK-CAART?

MuSK-CAART an investigational cell therapy that can be given to patients with anti-MuSK antibody positive Myasthenia Gravis (MuSK MG), who have active disease. Treatment with MuSK-CAART may potentially lead to complete and durable remission of disease.

Who can participate in the MusCAARTes™ Phase 1 Trial?

You may be able to take part if:

  • You are 18 years of age or older.
  • You have a confirmed diagnosis of MuSK-type MG with at least 1 prior positive anti-MuSK antibody test.
  • You have a history of a negative anti-AChR antibody test.
  • You have a positive anti-MuSK antibody test at screening.
  • You have MG severity Class I to IVa on the MGFA Clinical Classification.

Contact Us

Are you wondering if this clinical trial is right for you? A representative from the Cabaletta Study Team would be glad to discuss the study with you. Please email or call:

Cabaletta Study Team:

*Please include only your name and telephone number in the email. Someone from the Cabaletta Study Team will contact you to discuss the study.